thalidomide has been researched along with Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted in 4 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thalidomide has recently enjoyed renewed interest as a treatment in many disorders, including plasma cell leukemia." | 1.31 | Thalidomide-associated hepatitis: a case report. ( Fowler, R; Imrie, K, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Reddy, SP | 1 |
| Shah, VV | 1 |
| Wu, JJ | 1 |
| Zelenetz, AD | 1 |
| Wierda, WG | 1 |
| Abramson, JS | 1 |
| Advani, RH | 1 |
| Andreadis, CB | 1 |
| Bartlett, N | 1 |
| Bellam, N | 1 |
| Byrd, JC | 1 |
| Czuczman, MS | 1 |
| Fayad, LE | 1 |
| Glenn, MJ | 1 |
| Gockerman, JP | 1 |
| Gordon, LI | 1 |
| Harris, NL | 1 |
| Hoppe, RT | 1 |
| Horwitz, SM | 1 |
| Kelsey, CR | 1 |
| Kim, YH | 1 |
| Krivacic, S | 1 |
| LaCasce, AS | 1 |
| Nademanee, A | 1 |
| Porcu, P | 1 |
| Press, O | 1 |
| Pro, B | 1 |
| Reddy, N | 1 |
| Sokol, L | 1 |
| Swinnen, L | 1 |
| Tsien, C | 1 |
| Vose, JM | 1 |
| Yahalom, J | 1 |
| Zafar, N | 1 |
| Dwyer, MA | 1 |
| Naganuma, M | 1 |
| Fowler, R | 1 |
| Imrie, K | 1 |
| Raufman, JP | 1 |
| Lamps, LW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Safety of Post-transplant Alpha-beta Depleted T-cell Infusion Following Haploidentical Stem Cell Transplant (Haplo SCT)[NCT02193880] | 7 participants (Actual) | Interventional | 2014-10-09 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Patients will be monitored for Grade IV aGVHD and organ toxicity. Acute assessment will be done using the modified Keystone (Glucksberg) consensus criteria. (NCT02193880)
Timeframe: From baseline and before day +100 of transplant.
| Intervention | Participants (Count of Participants) |
|---|---|
| Alpha-beta Depleted T-cell Infusion | 0 |
Patients will be monitored for Grade IV cGVHD and organ toxicity. Chronic assessment will be done using the conventional criteria. (NCT02193880)
Timeframe: From baseline and before day +100 of transplant.
| Intervention | Participants (Count of Participants) |
|---|---|
| Alpha-beta Depleted T-cell Infusion | 0 |
4 other studies available for thalidomide and Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted
| Article | Year |
|---|---|
Apremilast for a psoriasis patient with HIV and hepatitis C.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Hepatitis C; HIV Infections; Humans; Male; Middle Aged; Pso | 2017 |
Non-Hodgkin's lymphomas, version 1.2013.
Topics: Antineoplastic Agents; Hepatitis B; Hepatitis B Antibodies; Hepatitis B Surface Antigens; Hepatitis | 2013 |
Thalidomide-associated hepatitis: a case report.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liv | 2001 |
Thalidomide-induced normalization of serum ALT levels in a patient with hepatitis C.
Topics: Alanine Transaminase; Female; Hepatitis C; Humans; Immunosuppressive Agents; Middle Aged; Thalidomid | 2001 |